This paper is in the following e-collection/theme issue:

Statistical Methods for Surveillance and Population Health (148) Cancer Survivorship (252) Clinical Informatics (918) Descriptive Epidemiology and Population Size Estimates (87) eHealth Service, Product, Resource Reviews (26) Health Care Quality and Health Services Research (252)

Published on in Vol 9 (2023)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/49968, first published .
Nasopharyngeal Cancer Incidence and Mortality in 185 Countries in 2020 and the Projected Burden in 2040: Population-Based Global Epidemiological Profiling

Nasopharyngeal Cancer Incidence and Mortality in 185 Countries in 2020 and the Projected Burden in 2040: Population-Based Global Epidemiological Profiling

Nasopharyngeal Cancer Incidence and Mortality in 185 Countries in 2020 and the Projected Burden in 2040: Population-Based Global Epidemiological Profiling

Authors of this article:

Yanting Zhang1 Author Orcid Image ;   Harriet Rumgay2 Author Orcid Image ;   Mengmeng Li3, 4 Author Orcid Image ;   Sumei Cao3, 4 Author Orcid Image ;   Wanqing Chen5 Author Orcid Image
Article Authors Cited by (11) Tweetations (8) Metrics

Journals

  1. Li H, Liang B, Gao X, Peng Y, Liu Q, Qiu L, Lin J. Cathepsin B-Activated PET Tracer for In Vivo Tumor Imaging. Molecular Pharmaceutics 2024;21(3):1382 View
  2. Wang R, Ke R, Yu Y, Lu G, Wu S. Addition of nimotuzumab to concurrent chemoradiotherapy after induction chemotherapy improves outcomes of patients with locally advanced nasopharyngeal carcinoma. Frontiers in Pharmacology 2024;15 View
  3. Makowska A, Weiskirchen R. Nasopharyngeal Carcinoma Cell Lines: Reliable Alternatives to Primary Nasopharyngeal Cells?. Cells 2024;13(7):559 View
  4. Chen Z, Ling J, Zhang S, Feng Y, Xie Y, Liu X, Hou T. Predicting the overall survival and progression‐free survival of nasopharyngeal carcinoma patients based on hemoglobin, albumin, and globulin ratio and classical clinicopathological parameters. Head & Neck 2024 View
  5. Shen H, Zhang C, Li S, Liang Y, Lee L, Aggarwal N, Wun K, Liu J, Nadarajan S, Weng C, Ling H, Tay J, Wang D, Yao S, Hwang I, Lee Y, Chang M. Prodrug-conjugated tumor-seeking commensals for targeted cancer therapy. Nature Communications 2024;15(1) View
  6. Jiménez-Labaig P, Rullan A, Hernando-Calvo A, Llop S, Bhide S, O’Leary B, Braña I, Harrington K. A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies. Cancer Treatment Reviews 2024;128:102772 View
  7. Xiao M, Tu L, Zhou T, He Y, Li X, Zuo Q. Predictive model based on multiple immunofluorescence quantitative analysis for pathological complete response to neoadjuvant immunochemotherapy in lung squamous cell carcinoma. Frontiers in Oncology 2024;14 View
  8. Fatima K, Andleeb A, Nasreen S, Sofi M, Wani U, Rasool M, Najmi A, Qamar S, Ahmad N, Ryhan R. Induction versus Adjuvant Chemotherapy Combined with Concurrent Chemoradiation: What Is Beneficial in Locally Advanced Nasopharyngeal Carcinoma—A 5-Year Comparative Study at a Tertiary Care Center in North India. South Asian Journal of Cancer 2024 View
  9. Yu Y, Lu G, Wang R, Song Y, Wu S. Additional PD-1 inhibitor improves complete response to induction chemotherapy in locally advanced nasopharyngeal carcinoma. Frontiers in Immunology 2024;15 View
  10. Lei S, Chen L, Ji P, Li K, Li Q, Huang C, Wang G, Ma J, Guo R, Tang L. Global burdens of nasopharyngeal carcinoma in children and young adults and predictions to 2040. Oral Oncology 2024;155:106891 View
  11. Sun B, Yuan Z, Wang M, Xu L, Feng J, Chen J. The chemokine CCL14 is a potential biomarker associated with immune cell infiltration in lung adenocarcinoma. Discover Oncology 2024;15(1) View